Autolus Therapeutics (AUTL) to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to Autolus Therapeutics (AUTL) to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 8, 2022 4:03 PM EST
Development milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus pivotal FELIX Phase 2 trial, announced in a separate press release today
Manufacturing milestone of $35m achieved as a result of completion of planned activities supporting the performance and qualification of the obecabtagene autoleucel (obe-cel) manufacturing process
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Blackstone... More
December 8, 2022 4:02 PM EST
Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)
Encouraging safety data observed, with 3% Grade 3 Cytokine Release Syndrome (CRS) and 8% Grade 3 Immune effector cell-associated neurotoxicity syndrome (ICANS) in 92 patients treated Achievement of development milestone has triggered payment of $35m from Blackstone Life Sciences, announced in a separate press release todayThe trial has completed screening patients for entry into the morphological cohort
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:... More
